Myriad Pharmaceuticals, Inc. (Nasdaq: MYRX) today announced the presentation of clinical data from two separate Phase 2a combination drug studies ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE